Risks of strict glycaemic control in diabetic nephropathy

MH De Borst, G Navis - Nature Reviews Nephrology, 2015 - nature.com
Nature Reviews Nephrology, 2015nature.com
A 6-year follow-up study of the ADVANCE trial participants reports that intensive glycaemic
control is renoprotective—but does not reduce mortality—in patients with type 2 diabetes
mellitus. By contrast, a post hoc analysis of the ACCORD trial suggests that intensive
glycaemic control might increase mortality in patients with diabetic nephropathy.
A 6-year follow-up study of the ADVANCE trial participants reports that intensive glycaemic control is renoprotective—but does not reduce mortality—in patients with type 2 diabetes mellitus. By contrast, a post hoc analysis of the ACCORD trial suggests that intensive glycaemic control might increase mortality in patients with diabetic nephropathy.
nature.com